News

Member Portal

Zynteglo Approved as Gene Therapy for Rare Blood Disorder

August 17, 2022

FDA Approves Targeted Therapy for HER2-Low Breast Cancer

August 6, 2022

Nubeqa Receives New Indication for Prostate Cancer

August 5, 2022

FDA Approves New Juvéderm Cosmetic Drug

August 3, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in September

August 1, 2022

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager

By submitting this form, you are consenting to receive marketing emails from: Benecard Services, LLC. (Lawrenceville, NJ 08648), https://www.benecard.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact.

News

Zynteglo Approved as Gene Therapy for Rare Blood Disorder

Xofluza

Jynneos

FDA Approves Targeted Therapy for HER2-Low Breast Cancer

Nubeqa Receives New Indication for Prostate Cancer

Calquence Tablet

FDA Approves New Juvéderm Cosmetic Drug

Cimerli

Brand Medications with Generic Alternatives Anticipated to be Approved in September

Benefit Advisors & Employees - Want to know more?

Benecard

Newsletter